432038-96-5|CP-5609|Pyridinium, 1-(2-amino-2-oxoethyl)-3-((2-((4S,5R,6S)-2-carboxy-6-((1R)-1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo(3.2.0)hept-2-en-3-yl)imidazo(5,1-b)thiazol-7-yl)carbonyl)-, inner salt|-范德生物科技公司

CP-5609

NMR下载 COA and HPLC MSDS下载
names：
Pyridinium, 1-(2-amino-2-oxoethyl)-3-((2-((4S,5R,6S)-2-carboxy-6-((1R)-1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo(3.2.0)hept-2-en-3-yl)imidazo(5,1-b)thiazol-7-yl)carbonyl)-, inner salt
CAS号：
432038-96-5
MDL Number：
MF(分子式)： C23H21N5O6S MW(分子量)： 495.51
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	CP-5609
英文别名	CP-5609; CP 5609; CP5609; ME-1036; ME 1036;ME1036; UNII-33501R83O2.
CAS号	432038-96-5
Inchi	InChI=1S/C23H21N5O6S/c1-10-15(19(23(33)34)28-18(10)16(11(2)29)21(28)32)13-7-27-9-25-17(22(27)35-13)20(31)12-4-3-5-26(6-12)8-14(24)30/h3-7,9-11,16,18,29H,8H2,1-2H3,(H2-,24,30,33,34)/t10-,11+,16+,18+/m0/s1
InchiKey	LZKPUSJSJVEXAW-WDXSGGTDSA-N
分子式 Formula	C23H21N5O6S
分子量 Molecular Weight	495.51
溶解度Solubility
性状	Solid powder
储藏条件 Storage conditions	Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years).

产品说明	CP-5609(CAS:432038-96-5):仅限应用于工业或者科学研究过程中非医疗目的，不应用于人类或动物的临床诊断以及治过程疗，该产品非药用，非食用。
Introduction	CP-5609 is a novel carbapenem with enhanced antimicrobial activities.
Application1
Application2
Application3

警示图
危险性	Warning
危险性警示
安全声明
安全防护
备注

[1]Hirai Y, Takahata S, Yamada K, Ida T, Maebashi K. Correlation of the antimicrobial activity of ME1036 with its binding affinities to the penicillin-binding proteins from Streptococcus pneumoniae strains. J Antibiot (Tokyo). 2011 Nov;64(11):741-6. doi: 10.1038/ja.2011.76. Epub 2011 Aug 24. PubMed PMID: 21863036.

[2]Morrissey I, Biek D, Janes R. ME1036, a novel carbapenem, with enhanced activity against clinical isolates causing bacteraemic community-acquired pneumonia. J Antimicrob Chemother. 2009 Jul;64(1):209-10. doi: 10.1093/jac/dkp163. Epub 2009 May 9. PubMed PMID: 19429928.

[3] Yanagihara K, Ohnishi Y, Morinaga Y, Nakamura S, Kurihara S, Seki M, Izumikawa K, Kakeya H, Yamamoto Y, Yamada Y, Kohno S, Kamihira S. Efficacy of ME1036 against meticillin-resistant Staphylococcus aureus and vancomycin-insensitive S. aureus in a model of haematogenous pulmonary infection. Int J Antimicrob Agents. 2008 Nov;32(5):401-4. doi: 10.1016/j.ijantimicag.2008.04.030. Epub 2008 Aug 19. PubMed PMID: 18715761.

[4] Fenoll A, Aguilar L, Robledo O, Giménez MJ, Granizo JJ, Biek D, Tarragó D. In vitro activity of ME1036 versus other beta-lactams against penicillin-resistant Streptococcus pneumoniae serotypes exhibiting higher amoxicillin than penicillin MIC. J Antimicrob Chemother. 2008 Nov;62(5):1156-8. doi: 10.1093/jac/dkn314. Epub 2008 Jul 30. PubMed PMID: 18667449.

[5] Villegas-Estrada A, Lee M, Hesek D, Vakulenko SB, Mobashery S. Co-opting the cell wall in fighting methicillin-resistant Staphylococcus aureus: potent inhibition of PBP 2a by two anti-MRSA beta-lactam antibiotics. J Am Chem Soc. 2008 Jul 23;130(29):9212-3. doi: 10.1021/ja8029448. Epub 2008 Jun 27. PubMed PMID: 18582062; PubMed Central PMCID: PMC2747592.

6: Sader HS, Fritsche TR, Jones RN. Antimicrobial activities of Ceftaroline and ME1036 tested against clinical strains of community-acquired methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2008 Mar;52(3):1153-5. doi: 10.1128/AAC.01351-07. Epub 2008 Jan 7. PubMed PMID: 18180353; PubMed Central PMCID: PMC2258508.7: Dalziel C, Turner B. Interscience conference on antimicrobial agents and chemotherapy--46th annual meeting. Release of data for Dc-159a, and other agents. 27-30 September 2006, San Francisco, CA, USA. IDrugs. 2006 Nov;9(11):765-7. PubMed PMID: 17096295.8: Nagura J, Kijima K, Kurazono M, Takahata S, Sugano T, Tanaka Y, Hirai Y, Yamada K, Takayama Y, Shitara E, Yonezawa M. Therapeutic effect of ME1036 on endocarditis experimentally induced by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2005 Aug;49(8):3526-8. PubMed PMID: 16048975; PubMed Central PMCID: PMC1196270.9: Maeda K, Ida T, Sanbongi Y, Suzuki T, Fukushima T, Kurazono M, Yonezawa M, Ubukata K, Inoue M. Comparison of activities of beta-lactam antibiotics against Streptococcus pneumoniae with recombinant penicillin-binding protein genes from a penicillin-resistant strain. J Infect Chemother. 2005 Apr;11(2):107-11. PubMed PMID: 15856382.10: Kurazono M, Ida T, Yamada K, Hirai Y, Maruyama T, Shitara E, Yonezawa M. In vitro activities of ME1036 (CP5609), a novel parenteral carbapenem, against methicillin-resistant staphylococci. Antimicrob Agents Chemother. 2004 Aug;48(8):2831-7. PubMed PMID: 15273088; PubMed Central PMCID: PMC478537.1

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

SDS 1.0 英文

展开